Home › Type 1 Diabetes › NCT07356089
Twiist Postmarket Surveillance Study for Type 1 Diabetes
RecruitingObservational study
Twiist Postmarket Surveillance Study in Adults and Youth With Type 1 Diabetes
Who can join
Ages 6 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Willing and able to provide informed consent (or a parent or other legally authorized representative) * Age ≥ 6 years old * Diagnosis of T1D * Currently using twiist AID system, with initiation of twiist within 90 days of enrollment * Willing to only use an insulin approved for the pump * Residing in United States * Willing to use twiist in accordance with the user manual * Willing to have the study use the twiist data and any information that has been provided to Sequel Medtech, LLC or customer support since twiist was started * Willing to complete surveys at the beginning of the study and then monthly for 12 months * Willing to be contacted if clarification or further information is needed for any events reported on a survey or to customer support * Willing to provide medical records or sign a record release for any hospitalizations * Has cell service or if not, will have access to WIFI at least once a week * For females, not pregnant or planning pregnancy in the next 12 months * Able to speak and read English * Able to obtain documentation of HbA1c result obtained within 6 months prior to twiist initiation Exclusion Criteria: * Any form of diabetes other than T1D * Receiving dialysis for end-stage renal disease
About the study
The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
What is being tested
- twiist Automated Insulin Delivery System (device)
Sponsor: Deka Research and Development · Participants: 1,875 · Started: Dec 9, 2025
Contact the study team
Official record on ClinicalTrials.gov — NCT07356089
Locations in the U.S.
| Florida | Jaeb Center for Health Research, Tampa |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.